These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 24249923)
21. Prevalence of Metabolic Syndrome in Patients with Schizophrenia in Korea: A Multicenter Nationwide Cross-Sectional Study. Lee JS; Kwon JS; Kim D; Kim SW; Kim JJ; Kim JH; Nam HJ; Ryu S; Park IH; An SK; Oh HS; Won S; Lee K; Lee KY; Lee SH; Lee YS; Yi JS; Hong KS; Joo YH Psychiatry Investig; 2017 Jan; 14(1):44-50. PubMed ID: 28096874 [TBL] [Abstract][Full Text] [Related]
22. Second generation antipsychotic-induced mitochondrial alterations: Implications for increased risk of metabolic syndrome in patients with schizophrenia. Scaini G; Quevedo J; Velligan D; Roberts DL; Raventos H; Walss-Bass C Eur Neuropsychopharmacol; 2018 Mar; 28(3):369-380. PubMed ID: 29449054 [TBL] [Abstract][Full Text] [Related]
24. Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. Fleischhacker WW; Siu CO; Bodén R; Pappadopulos E; Karayal ON; Kahn RS; Int J Neuropsychopharmacol; 2013 Jun; 16(5):987-95. PubMed ID: 23253821 [TBL] [Abstract][Full Text] [Related]
25. The metabolic syndrome in untreated schizophrenia patients: prevalence and putative mechanisms. Reddy SM; Goudie CT; Agius M Psychiatr Danub; 2013 Sep; 25 Suppl 2():S94-8. PubMed ID: 23995153 [TBL] [Abstract][Full Text] [Related]
26. Leukocyte telomere length in Hispanic schizophrenia patients under treatment with olanzapine. Monroy-Jaramillo N; Rodríguez-Agudelo Y; Aviña-Cervantes LC; Roberts DL; Velligan DI; Walss-Bass C J Psychiatr Res; 2017 Jul; 90():26-30. PubMed ID: 28226264 [TBL] [Abstract][Full Text] [Related]
27. Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype. Zhang Y; Chen M; Chen J; Wu Z; Yu S; Fang Y; Zhang C Psychopharmacology (Berl); 2014 May; 231(10):2211-8. PubMed ID: 24448899 [TBL] [Abstract][Full Text] [Related]
28. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine. Krzystanek M; Krupka-Matuszczyk I Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416 [TBL] [Abstract][Full Text] [Related]
29. Complement 3 and metabolic syndrome induced by clozapine: a cross-sectional study and retrospective cohort analysis. Zhang C; Zhang Y; Cai J; Chen M; Song L Pharmacogenomics J; 2017 Jan; 17(1):92-97. PubMed ID: 26503818 [TBL] [Abstract][Full Text] [Related]
30. Genetic variants of microsomal triglyceride transfer protein (MTTP) are associated with metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. Liou YJ; Tsai SJ; Wang YC; Bai YM; Hong CJ J Clin Psychopharmacol; 2013 Jun; 33(3):313-8. PubMed ID: 23609384 [TBL] [Abstract][Full Text] [Related]
31. Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies. Bou Khalil R Clin Neuropharmacol; 2012; 35(3):141-7. PubMed ID: 22592510 [TBL] [Abstract][Full Text] [Related]
32. Leptin/Adiponectin ratio as a potential biomarker for metabolic syndrome in patients with schizophrenia. Chen VC; Chen CH; Chiu YH; Lin TY; Li FC; Lu ML Psychoneuroendocrinology; 2018 Jun; 92():34-40. PubMed ID: 29625373 [TBL] [Abstract][Full Text] [Related]
33. Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. Liou YJ; Bai YM; Lin E; Chen JY; Chen TT; Hong CJ; Tsai SJ Pharmacogenomics J; 2012 Feb; 12(1):54-61. PubMed ID: 20877301 [TBL] [Abstract][Full Text] [Related]
34. Association between SREBF2 gene polymorphisms and metabolic syndrome in clozapine-treated patients with schizophrenia. Yang L; Chen J; Liu D; Yu S; Cong E; Li Y; Wu H; Yue Y; Zuo S; Wang Y; Liang S; Shi Y; Shi S; Xu Y Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jan; 56():136-41. PubMed ID: 25201120 [TBL] [Abstract][Full Text] [Related]
35. Association of metabolic syndrome with schizophrenia. Bajaj S; Varma A; Srivastava A; Verma AK Indian J Endocrinol Metab; 2013 Sep; 17(5):890-5. PubMed ID: 24083172 [TBL] [Abstract][Full Text] [Related]
36. Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics--results from a German observational study. Kraemer S; Minarzyk A; Forst T; Kopf D; Hundemer HP BMC Psychiatry; 2011 Nov; 11():173. PubMed ID: 22044502 [TBL] [Abstract][Full Text] [Related]
37. Clozapine use and sedentary lifestyle as determinants of metabolic syndrome in outpatients with schizophrenia. Eskelinen S; Sailas E; Joutsenniemi K; Holi M; Suvisaari J Nord J Psychiatry; 2015 Jul; 69(5):339-45. PubMed ID: 25981178 [TBL] [Abstract][Full Text] [Related]
38. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020. Yıldız M; Osman E Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516 [TBL] [Abstract][Full Text] [Related]
39. Metabolomic profiling of schizophrenia patients at risk for metabolic syndrome. Paredes RM; Quinones M; Marballi K; Gao X; Valdez C; Ahuja SS; Velligan D; Walss-Bass C Int J Neuropsychopharmacol; 2014 Aug; 17(8):1139-48. PubMed ID: 24565079 [TBL] [Abstract][Full Text] [Related]
40. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Correll CU; Frederickson AM; Kane JM; Manu P Bipolar Disord; 2008 Nov; 10(7):788-97. PubMed ID: 19032710 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]